… thrombolytic administered within 4.5 hours of stroke symptoms. Tenecteplase (TNK) is FDA-approved for STEMI, but its off-label use for AIS …
TNK
This drug is selected. Its supporting articles are shown below.
Articles mentioning TNK
9 articles · page 1 of 1…, and functional dependency (28.1% vs 22.8%, p=0.37).Conclusion TNK and tPA demonstrated comparable safety and mortality in BAO tre…
E-272 Tenecteplase versus alteplase for acute ischemic stroke: a propensity matched TriNetX Analysis
… lower mortality at 6 months, 1 year, and 3 years compared with alteplase, without increased intracerebral hemorrhage. Early cognitive im…
…ytic therapy with its single bolus administration compared with alteplase. Moreover, its high specificity for fibrin may contribute to a …
…289 Figure 1Recanalization rate by occlusion location following tenecteplase administration. Spontaneous recanalization occurred more freque…
…Background Tenecteplase (TNK) has emerged as an alternative to alteplase for acute isch…
…mRS 0–2 (OR: 1.41, 95% CI: 1.14 to 1.75, p=0.001) compared with alteplase.Conclusions Thrombolysis with TNK is not associated with an inc…
…ficantly help enhance the accuracy of catheter placement, while tenecteplase (TNK), a third-generation thrombolytic agent, offers stronger c…
…. A total of 87.5% of patients received TNK, and 12.5% received tPA.Acute CAS was performed in 58.3% of cases. A retrograde (intrac…